All In Biotech

Drug Trial Radar · NCT07935590

Study of Modzatinib (ATI-2138) in Adult Participants With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies

A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy and Safety of Modzatinib (ATI-2138) in Adult Participants With Biopsy-Proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies (ALPHA)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

102

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Mar 2029

Study completion Apr 2029

Sponsor

Lead sponsor
Aclaris Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates modzatinib versus placebo in participants with biopsy-proven forms of moderate-to-severe lichen planus (LP).

Conditions

  • Lichen Planus

Interventions

  • ModzatinibDrug

    Oral tablets

  • PlaceboDrug

    Oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants With OLP: Change From Baseline in Activity Score of the Oral Disease Severity Score (ODSS) at Week 16Time frame: Baseline, Week 16
  2. Participants With CLP: Change From Baseline in Modified Lichen Planus Area and Severity Index (LPASI) Score at Week 16Time frame: Baseline, Week 16
  3. Participants With LPP: Change From Baseline in Lichen Planopilaris Activity Index (LPPAI) Score at Week 24Time frame: Baseline, Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aclaris Clinical Site

    Savannah, Georgia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.